ANKRD16

Across TCGA pan-cancer cohorts, ANKRD16 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANKRD16 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANKRD16 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD16 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC and LSCC are the cancer types where ANKRD16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.931	0.618	<.001	73	view →
LSCC	OS	Median	III,IV	0.478	0.866	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ANKRD16–PDAC (DFS)

Open the PDAC breakdown →